Publicacions en col·laboració amb investigadors/es de Hospital Universitario La Paz (50)

2024

  1. COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant

    Cancers, Vol. 16, Núm. 2

2023

  1. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

  2. Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25

  3. NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells

    Frontiers in Immunology, Vol. 14

  4. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study

    BMJ open, Vol. 13, Núm. 7, pp. e071371

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits

    Leukemia and Lymphoma

  3. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group

    Blood cancer journal, Vol. 12, Núm. 4, pp. 76

2021

  1. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma

    Blood Cancer Journal, Vol. 11, Núm. 8

  2. Natural killer cells efficiently target multiple myeloma clonogenic tumor cells

    Cancer Immunology, Immunotherapy, Vol. 70, Núm. 10, pp. 2911-2924

  3. Optimizing the procedure to manufacture clinical‐grade NK cells for adoptive immunotherapy

    Cancers, Vol. 13, Núm. 3, pp. 1-24

  4. Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL–Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 5, pp. 328-337.e1

2020

  1. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  2. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study

    Journal of Hematology and Oncology, Vol. 13, Núm. 1

  3. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

    Blood Cancer Journal, Vol. 10, Núm. 10

2019

  1. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy

    Frontiers in Immunology, Vol. 10

  2. Immediate effects of dasatinib on the migration and redistribution of naïve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients

    Frontiers in Pharmacology, Vol. 10

  3. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data

    BMC Cancer, Vol. 19, Núm. 1

2018

  1. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

    British Journal of Haematology

  2. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia

    Cancer Letters, Vol. 422, pp. 107-117